Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Pulmonary Medicine · Autoimmune Interstitial Lung Disease–Arthritis Syndrome

Treatment Strategies and Managing Risks

At a Glance

Autoimmune ILD treatment is individualized: immunosuppressants such as steroids, mycophenolate, or azathioprine control active inflammation, while nintedanib may slow progressive scarring. Close monitoring is essential because treatment can increase infection and organ risks.

The primary goal of treating autoimmune interstitial lung disease (ILD) is to stabilize your condition—stopping further damage to the lungs rather than achieving a “cure” for existing scars [1]. Because your immune system is attacking your healthy lung tissue, the main strategy is to “turn down the volume” of that immune response using immunosuppressants [2]. Treatment decisions are highly individualized based on your specific connective-tissue disease, phenotype, and progression.

Immunosuppressive Strategies

Depending on the specific condition and severity, the first step often aims to reduce active inflammation. This usually involves a two-part strategy [1][3]:

  1. Glucocorticoids (Steroids): Medications like prednisone are used to act quickly against inflammation [1]. (Note: In certain conditions like Systemic Sclerosis, high-dose steroids are used very cautiously or avoided due to a risk of renal crisis).
  2. Steroid-Sparing Agents: To help you taper off steroids, doctors add “maintenance” drugs that manage the immune system long-term.
    • Mycophenolate (CellCept): Often a preferred choice, because it is generally well-tolerated [4][5].
    • Azathioprine (Imuran): Another common option, though it requires frequent blood tests to monitor liver enzymes [6][5].

Treatment for Specific Subtypes

Different autoimmune diseases require different toolkits.

RA-ILD (Rheumatoid Arthritis)

In addition to mycophenolate or azathioprine, patients with RA-ILD may be treated with rituximab, a medication given by IV infusion that targets specific immune cells (B-cells) [7][8].

The Anti-MDA5 “Triple Therapy” Protocol

If you have anti-MDA5-associated disease and develop clinically severe or rapidly progressive ILD, expert consensus favors an aggressive “triple therapy” approach rather than a slow step-up [9][10]:

  • High-dose steroids (often given via IV) [9].
  • A calcineurin inhibitor (like tacrolimus or cyclosporine) [9].
  • IV Cyclophosphamide, a powerful immunosuppressant [9][11].

Managing Progressive Scarring (Fibrosis)

If you develop a progressive pulmonary fibrosis (PPF) phenotype—meaning documented clinical, physiologic, or radiologic decline despite appropriate management—your doctor may add an antifibrotic medication called nintedanib (Ofev) [12][13].

Nintedanib does not affect the immune system directly; instead, it blocks the chemical signals that tell the body to build scar tissue [14]. It is important to know that nintedanib does not reverse existing scar tissue, but in major trials, it reduced the relative rate of lung function decline by about 50% [15][16].

Important Risks and Harms

While these medications are essential for protecting your lungs, they come with significant risks that require strict monitoring.

  • Infection Risk: Because your immune system is suppressed, you are at higher risk for common and “opportunistic” infections [17][18]. Depending on your risk, your doctor may prescribe an antibiotic (like Bactrim) to prevent PJP pneumonia [19]. This is an individualized decision, not a routine rule for everyone.
  • Cyclophosphamide: Carries risks of bladder toxicity, bone marrow suppression, infertility/ovarian failure, and long-term malignancy risk.
  • Mycophenolate: Is highly teratogenic (causes severe birth defects) and requires strict contraception and pregnancy planning.
  • Calcineurin Inhibitors (Tacrolimus/Cyclosporine): Can cause kidney injury and high blood pressure.
  • Rituximab: Carries a risk of Hepatitis B reactivation; baseline screening is required.
  • Gastrointestinal Issues: Nintedanib frequently causes diarrhea, which may require dose adjustments [16][15].
  • Blood, Liver, and Steroid Monitoring: Drugs like azathioprine affect liver function and blood counts [6][20]. Long-term steroids risk diabetes, osteoporosis, and mood changes.

If you develop a fever, a new cough, or feel suddenly unwell while on these treatments, you must contact your medical team immediately [21]. Always discuss vaccination timing (especially live vaccines) with your prescribing doctor.

Common questions in this guide

What medicines are commonly used to treat autoimmune ILD?
Doctors may use corticosteroids such as prednisone to calm active inflammation, often alongside a steroid-sparing medicine such as mycophenolate or azathioprine. The choice depends on the autoimmune disease, the pattern and severity of lung involvement, and how the condition is changing over time.
What is anti-MDA5 triple therapy for autoimmune ILD?
For severe or rapidly worsening anti-MDA5-associated ILD, specialists may start intensive treatment with high-dose steroids, a calcineurin inhibitor such as tacrolimus or cyclosporine, and intravenous cyclophosphamide. This approach requires close monitoring because each medicine can cause serious side effects.
When might nintedanib be used for autoimmune ILD?
Nintedanib may be added when the lungs show progressive pulmonary fibrosis despite appropriate treatment. It slows the rate of further lung-function decline but does not remove existing scar tissue or directly suppress the immune system. Diarrhea is a common side effect and may require dose changes.
What are the main risks of immunosuppressive treatment?
These medicines can increase the risk of common and opportunistic infections and may affect the blood counts, liver, kidneys, blood pressure, fertility, or pregnancy depending on the drug. Long-term steroids can also contribute to diabetes, osteoporosis, and mood changes, so regular monitoring is important.
What monitoring is needed during treatment for autoimmune ILD?
Monitoring may include blood counts, liver tests, kidney function, blood pressure, and checks for medication-specific risks. People taking rituximab need hepatitis B screening, and people taking mycophenolate need strict pregnancy planning and contraception because it can cause severe birth defects.
Should everyone taking immunosuppressants receive a PJP prevention antibiotic?
No, PJP prevention is an individualized decision rather than a routine requirement for everyone. Your doctor will consider the medicines and doses you take, the intensity of immune suppression, and your other risk factors before recommending an antibiotic such as trimethoprim-sulfamethoxazole.
What should I do if I develop a fever or new cough during treatment?
Contact your medical team promptly if you develop a fever, a new cough, or suddenly feel unwell while taking these medicines. Ask your prescribing team when vaccines should be given, especially before treatment and before any live vaccine.

Get notified when new evidence is published on Autoimmune interstitial lung disease-arthritis syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (21)
  1. 1

    2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.

    Johnson SR, Bernstein EJ, Bolster MB, et al.

    Arthritis care & research 2024; (76(8)):1051-1069 doi:10.1002/acr.25348.

    PMID: 38973731
  2. 2

    Distinct phenotypes and prognosis between Jo-1 and non-Jo-1 subtypes in anti-synthetase syndrome: a retrospective cohort study from China.

    Zhang X, Wang L, Cheng Q, et al.

    Clinical rheumatology 2026; (45(2)):1199-1207 doi:10.1007/s10067-025-07849-3.

    PMID: 41331199
  3. 3

    ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease.

    Antoniou KM, Distler O, Gheorghiu AM, et al.

    The European respiratory journal 2026; (67(1)) doi:10.1183/13993003.02533-2024.

    PMID: 40907995
  4. 4

    Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline.

    Raghu G, Montesi SB, Silver RM, et al.

    American journal of respiratory and critical care medicine 2024; (209(2)):137-152 doi:10.1164/rccm.202306-1113ST.

    PMID: 37772985
  5. 5

    Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease.

    Oldham JM, Lee C, Valenzi E, et al.

    Respiratory medicine 2016; (121()):117-122 doi:10.1016/j.rmed.2016.11.007.

    PMID: 27888985
  6. 6

    Azathioprine for Connective Tissue Disease-Associated Interstitial Lung Disease.

    Boerner EB, Cuyas M, Theegarten D, et al.

    Respiration; international review of thoracic diseases 2020; (99(8)):628-636 doi:10.1159/000508540.

    PMID: 32663826
  7. 7

    Divergent approaches to rheumatoid arthritis-associated interstitial lung disease: a comparative analysis of international clinical practice guidelines.

    Garcia-Salinas R, Chávez-Lopez M, Gómez RA, et al.

    Rheumatology international 2026; (46(11)).

    PMID: 42888356
  8. 8

    Contemporary Guideline Perspectives on Methotrexate and Biologic/Targeted Synthetic Disease-Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis-Associated Interstitial Lung Disease.

    Yamakawa H, Yokosawa M

    Internal medicine (Tokyo, Japan) 2026; doi:10.2169/internalmedicine.8144-26.

    PMID: 42649071
  9. 9

    Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease.

    Romero-Bueno F, Diaz Del Campo P, Trallero-Araguás E, et al.

    Seminars in arthritis and rheumatism 2020; (50(4)):776-790 doi:10.1016/j.semarthrit.2020.03.007.

    PMID: 32534273
  10. 10

    Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: A systematic review.

    McPherson M, Economidou S, Liampas A, et al.

    Seminars in arthritis and rheumatism 2022; (53()):151959 doi:10.1016/j.semarthrit.2022.151959.

    PMID: 35134633
  11. 11

    Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High-Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis.

    Tsuji H, Nakashima R, Hosono Y, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2020; (72(3)):488-498 doi:10.1002/art.41105.

    PMID: 31524333
  12. 12

    Antifibrotic therapy in progressive pulmonary fibrosis: a review of recent advances.

    Naqvi M, Hannah J, Lawrence A, et al.

    Expert review of respiratory medicine 2024; (18(6)):397-407 doi:10.1080/17476348.2024.2375420.

    PMID: 39039699
  13. 13

    Treatment of rheumatoid arthritis-associated interstitial lung disease: An appraisal of the 2023 ACR/CHEST guideline.

    Saavedra AA, Mueller KT, Kowalski EN, et al.

    Current treatment options in rheumatology 2024; (10(4)):43-60 doi:10.1007/s40674-024-00217-3.

    PMID: 39822854
  14. 14

    Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases.

    Cottin V, Richeldi L, Rosas I, et al.

    Respiratory research 2021; (22(1)):84 doi:10.1186/s12931-021-01668-1.

    PMID: 33726766
  15. 15

    Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial.

    Matteson EL, Kelly C, Distler JHW, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2022; (74(6)):1039-1047 doi:10.1002/art.42075.

    PMID: 35199968
  16. 16

    Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial.

    Matteson EL, Aringer M, Burmester GR, et al.

    Clinical rheumatology 2023; (42(9)):2311-2319 doi:10.1007/s10067-023-06623-7.

    PMID: 37209188
  17. 17

    Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial.

    Mankikian J, Caille A, Reynaud-Gaubert M, et al.

    The European respiratory journal 2023; (61(6)) doi:10.1183/13993003.02071-2022.

    PMID: 37230499
  18. 18

    New therapies in anti-MDA5 antibody-positive dermatomyositis.

    Yasui M, Iwamoto T, Furuta S

    Current opinion in rheumatology 2024; (36(1)):61-68 doi:10.1097/BOR.0000000000000979.

    PMID: 37682061
  19. 19

    Immunomodulatory treatment of interstitial lung disease.

    van den Bosch L, Luppi F, Ferrara G, Mura M

    Therapeutic advances in respiratory disease 2022; (16()):17534666221117002 doi:10.1177/17534666221117002.

    PMID: 35938712
  20. 20

    Mycophenolate mofetil versus cyclophosphamide plus in patients with connective tissue disease-associated interstitial lung disease: Efficacy and safety analysis.

    Wang P, Zhang L, Guo Q, et al.

    Open medicine (Warsaw, Poland) 2023; (18(1)):20230838 doi:10.1515/med-2023-0838.

    PMID: 38025531
  21. 21

    Acute exacerbation of interstitial lung disease associated with rheumatic disease.

    Luppi F, Sebastiani M, Salvarani C, et al.

    Nature reviews. Rheumatology 2022; (18(2)):85-96 doi:10.1038/s41584-021-00721-z.

    PMID: 34876670

This page explains treatment options and medication risks for autoimmune interstitial lung disease for informational purposes only and does not constitute medical advice. Your pulmonologist, rheumatologist, and prescribing team should guide decisions about your specific treatment.

Guide contents Autoimmune interstitial lung disease-arthritis syndrome
Research & Literature
04 Navigating Your Diagnosis and Testing 06 Active Monitoring and Daily Care